Sensorion

Sensorion Intangible Assets

The Intangible Assets of Sensorion (ALSEN.PA) as of Oct 9, 2026 is 746,000.00 EUR. In the previous year, Intangible Assets was 506,300.00 EUR — a change of 47.34% (higher).

Intangible Assets

746,000.00EUR

YoY

47.34%

Last updated:

Intangible Assets of Sensorion is 2024 746,000.00 EUR. Intangible Assets of Sensorion was 2023 506,300.00 EUR. It decreases by 47.34% higher compared to the previous year.

The Sensorion Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
821,000.00 EUR
Jan 1, 2018
871,700.00 EUR
Jan 1, 2019
720,600.00 EUR
Jan 1, 2020
589,600.00 EUR
Jan 1, 2021
569,700.00 EUR
Jan 1, 2022
478,300.00 EUR
Jan 1, 2023
506,300.00 EUR
Jan 1, 2024
746,000.00 EUR
The Sensorion Intangible Assets history
YEARIntangible AssetsYoY
746,000.00EUR+47.34%
506,300.00EUR+5.85%
478,300.00EUR-16.04%
569,700.00EUR-3.38%
589,600.00EUR-18.18%
720,600.00EUR-17.33%
871,700.00EUR+6.18%
821,000.00EUR-3.13%
847,500.00EUR—
Access this data via the Eulerpool API
Get Free API Key

Sensorion Stock analysis

What does Sensorion do? The company Sensorion SA is a French biotechnology company that specializes in developing innovative therapies for hearing and balance disorders. It was founded in 2009 and is headquartered in Montpellier. Sensorion SA's business model is based on researching and developing new drugs that can be used to treat inner ear diseases. These diseases often have severe effects on the quality of life and social interaction of those affected and represent a significant unmet medical need. Sensorion SA aims to develop innovative and effective therapies to address this need. The company specializes in two main areas: hearing disorders and balance disorders. In the field of hearing disorders, Sensorion SA focuses on developing drugs to treat sensorineural hearing loss. These disorders can be caused by various factors such as aging, noise exposure, or genetic predisposition and affect the inner ear. Sensorion SA has a promising pipeline of drugs in clinical development based on different mechanisms of action. These drugs aim to protect the inner ear and restore hearing function. In the field of balance disorders, Sensorion SA focuses on developing new drugs to treat dizziness and vestibular disorders. These disorders can be caused by factors such as aging, medications, or neurological diseases and affect the balance system in the inner ear. Sensorion SA also has a promising pipeline of drugs in clinical development in this area. Sensorion SA's products are not yet available on the market as they are still in development and undergoing clinical trials. However, the company works closely with academic and industry partners to test and validate its drugs. The development of new drugs is a lengthy and costly process that can take many years. However, Sensorion SA is confident that its therapies have the potential to improve the lives of many people. Overall, Sensorion SA has a promising business model based on the development of innovative therapies for hearing and balance disorders. The company has a promising pipeline of drugs in clinical development and works closely with partners to test and validate its products. If successful, their drugs could have a significant impact on the lives of people suffering from these diseases. Sensorion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sensorion stock

Intangible Assets of Sensorion is 746,000.00 EUR in 2024.

Intangible Assets of Sensorion changed from 506,300.00 EUR to 746,000.00 EUR, representing a 47.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Sensorion since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Sensorion historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Sensorion

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Sensorion